Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials

PURPOSE Accurate medication reconciliation is critical in oncology trials to mitigate drug-drug interactions, address eligibility, and enhance patient safety, especially given that patients with cancer often experience polypharmacy (≥5 medications) and medication lists in electronic medical records (EMRs) are often incomplete or outdated. To streamline screening for phase I trials, a pharmacist-led medication reconciliation televisit (MRT) model was implemented to improve baseline medication list accuracy and reduce in-clinic time. METHODS From December 2022 to January 2025, one MRT occurred for each adult patient screening for phase I trials, after trial consent but before registration. Pharmacists reviewed EMRs and dispense histories and then conducted structured phone interviews to review prescription, over-the-counter (OTC), herbal, and cannabis usage, including name, strength, dose, frequency, start dates, indications, and ingredients. Inactive medications were discontinued, allergies were updated, and patient concerns and medication details were documented. RESULTS